Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings (MTNB) has recorded zero cyber incidents and zero red-flag 8-K filings over the past 90 days, indicating a quiet recent period from an acute risk standpoint. However, absence of recent events in our near-term window does not rule out structural risks common to biotech firms, particularly around dilution exposure and financing runway. The full $49 Report extends the analysis to 12 months of filing history, quantifies shareholder dilution risk, maps the company's funding trajectory, and surfaces early AI-detected warning signals across SEC filings. The full $49 Report adds dilution risk scoring, complete 8-K context, financing history analysis, and AI risk signals across the full filing record.